Physician profile
Deepa Nagaraja
NPI 1396009734
$1,228.56
in general payments reported to CMS, 2019-2025
18 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.88 · 2020: $119 · 2021: $95.87 · 2022: $171 · 2023: $169 · 2024: $333 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $223.43 | 2019-2024 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $182.88 | 2019-2025 | Jynarque |
| Abbvie INC. | $124.41 | 2022 | |
| Travere Therapeutics, INC. | $92.52 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $85.86 | 2023-2025 | Acthar, Terlivaz |
| Novartis Pharmaceuticals Corporation | $81.11 | 2023-2025 | |
| Vifor Pharma, INC. | $65.38 | 2021-2024 | Veltassa |
| Fresenius USA Marketing, INC. | $65.35 | 2020-2025 | Velphoro |
| Aurinia Pharma U.S., INC. | $64.54 | 2021-2022 | |
| Daiichi Sankyo INC. | $45.88 | 2020-2023 | Injectafer |
| Calliditas Therapeutics US INC. | $42.99 | 2023-2025 | Tarpeyo |
| Amgen INC. | $42.89 | 2024-2025 | Tavneos |
| Lilly USA, LLC | $26.37 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $19.13 | 2024 | |
| Glaxosmithkline, LLC. | $18.66 | 2025 | Benlysta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $16.70 | 2023 | Kimyrsa, Vabomere, Rezzayo |
| Scpharmaceuticals INC. | $16.38 | 2025 | |
| Leadiant Biosciences, INC. | $14.08 | 2024 | Cystaran |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Nagaraja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.